Compugen Ltd.

NASDAQ:CGEN

Biotechnology

Healthcare
$1.96 +0.50%

+$0.01 today

Market cap
$185.66M
Beta
2.74
P/E (TTM)
5.4
EPS (TTM)
$0.37
52W Low $1.30High $3.24

Volume 0.15M

Average 0.48M

CGEN Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Compugen Ltd.NASDAQ: CGEN

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 94.56M shares rose 2.4% year over year, behind the +4.2% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +2.6% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.4% toward the trailing-twelve-month pace of +4.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
94.56M+0.3% QoQ
Last fiscal yearDec 2025
93.43M+4.4% YoY
LTMMar 2026
93.98M+4.2% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.4%——
1 year+4.4%——
3-year CAGR+2.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
93.43M USD
Year-over-year change
+4.4%
4-year CAGR
+2.6%

Weighted Avg Shares vs competitors

How CGEN compares with its peers on the latest reported figures

  • CGEN's LTM Mar 2026 weighted avg shares of 93.98M shares is the 2nd highest of the 9 companies compared; the peer median is 52.29M shares.
  • Its year-over-year change of +4.2% is the lowest of 9, against a peer median of +30.5%.
  • Over three fiscal years its annual growth of +2.6% compares with a peer median of +22.7%.
CGEN Competitors Peer median
Weighted Avg Shares for CGEN and competitors
Company Period LTM YoY 3-year CAGR
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026100.04M +230.0%+40.6%
CGENCompugen Ltd.LTM Mar 202693.98M +4.2%+2.6%
IPHAInnate Pharma S.A.FY202589.42M +10.3%+4.0%
MISTMilestone Pharmaceuticals Inc.LTM Mar 202686.73M +33.0%+25.5%
CRDFCardiff Oncology, Inc.LTM Mar 202667.15M +30.5%+15.3%
MOLNMolecular Partners AGLTM Mar 202637.43M +9.0%+4.7%
NVCTNuvectis Pharma, Inc.LTM Mar 202622.33M +21.4%+19.9%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 202612.8M +30.5%+47.3%
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 20269.62M +108.1%+40.5%
Peer median (excluding CGEN) 52.29M+30.5%+22.7%

Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6M7.5M33.46M27.86M72.76M
Cost of Revenue680K975K2M7.93M9.25M
Gross Profit5.32M6.53M31.46M19.93M63.51M
Gross Margin88.7%87.0%94.0%71.5%87.3%
Research & Development28.69M30.65M34.47M24.81M22.76M
Selling, General & Admin11.7M11.25M9.98M10.02M9.43M
Operating Expenses40.39M41.9M44.45M34.83M32.19M
Depreciation & Amortization461K482K476K486K475K
EBITDA(33.72M)(33.13M)(9.28M)(9.19M)35.87M
EBITDA Margin-562.0%-441.7%-27.7%-33.0%49.3%
Operating Income(35.07M)(35.37M)(12.99M)(14.89M)31.33M
Operating Margin-584.6%-471.7%-38.8%-53.4%43.1%
Interest Income894K1.44M3.24M5.24M4.41M
Interest Expense25K27K31K34K0
Other Income / Expenses871K1.74M3.21M5.18M4.07M
Income Before Tax(34.2M)(33.64M)(9.78M)(9.71M)35.4M
Pre-Tax Margin-570.0%-448.5%-29.2%-34.8%48.6%
Income Tax Expense058K8.97M4.52M54K
Net Income(34.2M)(33.69M)(18.75M)(14.23M)35.34M
Net Margin-570.0%-449.3%-56.1%-51.1%48.6%
EPS (Basic)(0.41)(0.39)(0.21)(0.16)0.38
EPS (Diluted)(0.41)(0.39)(0.21)(0.16)0.38
Weighted Avg Shares84.2M86.56M87.63M89.53M93.43M
Weighted Avg Shares (Diluted)84.2M86.56M87.63M89.53M93.82M

Compugen Ltd.

NASDAQ:CGEN

Intrinsic Alpha fair value

Locked

Current Price

$1.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.